- Reuters•23 hours ago
Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say. The yet-to-be-published studies involve drugs in a new class designed to enable the body's immune system to fight cancer. A recent trial of Merck's Keytruda showed that it worked better than chemotherapy as an initial treatment for advanced non-small cell lung cancer (NSCLC) in patients with high levels of a protein called PDL1, believed to help identify those most likely to benefit from this type of immunotherapy.
Discover why the baby boomers are benefiting the health care sector. Explore five health care stocks that are well positioned to meet customers' demands.
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||58.76 x 100|
|Ask||58.82 x 600|
|Day's Range||58.54 - 59.40|
|52wk Range||56.32 - 77.12|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||34.37|
|Avg Vol (3m)||9,385,026|
|Dividend & Yield||1.52 (2.59%)|